| abstract |
The present invention relates to novel 3,15-substituted estrone derivatives representing inhibitors of 17β-hydroxysteroid dehydrogenase type I (17β-HSD1), salts thereof, pharmaceutical preparations containing these compounds, and Related to the method of preparation of compounds. Furthermore, the present invention relates to the therapeutic use of said novel 3,15-substituted estrone derivatives, in particular steroid hormone dependent diseases or disorders (eg of 17β-hydroxysteroid dehydrogenase type I enzyme). It relates to their use in treating or preventing steroid hormone dependent diseases or disorders that require inhibition and / or need to reduce endogenous 17β-estradiol levels. In addition, the present invention further has no pure antagonistic binding affinity for the estrogen receptor to treat and prevent benign gynecological disorders, specifically endometriosis, Alternatively, it relates to the general use of selective 17β-hydroxysteroid dehydrogenase type I inhibitors that additionally have only pure antagonistic binding affinity for the estrogen receptor. |